0001723128-26-000011
SEC filingAmneal Pharmaceuticals reported strong financial performance for FY 2025, with net revenue increasing 8.0% to $3.02 billion from $2.79 billion in the prior year. Net income attributable to the company was $72.1 million, a significant improvement from a net loss of $73.9 million in FY 2024. This turnaround was driven by growth across all segments, particularly in Specialty (up 18.6%) and AvKARE (up 12.3%), along with a 58.1% increase in operating income to $394.1 million. The company generated $340.0 million in operating cash flow and ended the year with $282.0 million in cash and cash equivalents. Key forward-looking items include an estimated $110.0 million in 2026 capital expenditures and ongoing monitoring of tariff and trade developments that could impact costs and supply chains.
Amneal Pharmaceuticals delivered a robust financial performance in FY 2025, marked by significant revenue growth and a return to profitability. Consolidated net revenue reached $3.02 billion, an 8.0% increase from $2.79 billion in FY 2024. The company achieved operating income of $394.1 million, a substantial 58.1% improvement year-over-year. Net income attributable to Amneal Pharmaceuticals, Inc. was $72.1 million, a dramatic turnaround from a net loss attributable to the company of $73.9 million in the prior year. This performance was supported by strong cash generation, with net cash provided by operating activities of $340.0 million, up 15.2% from $295.1 million in FY 2024.
Revenue growth was broad-based across all three reportable segments. The Affordable Medicines segment, the largest contributor, grew 3.6% to $1.75 billion, primarily due to new product launches in 2025 and 2024 which contributed $122.6 million of year-over-year growth, along with strong volume growth partially offset by price erosion. The Specialty segment showed the strongest percentage growth, increasing 18.6% to $528.5 million, driven by increases of $58.1 million from CREXONT and $23.7 million from UNITHROID, partially offset by a $6.0 million decrease in out-licensing revenue for IPX203. The AvKARE segment grew 12.3% to $744.7 million, primarily from growth in the government label channel due to new product introductions, partially offset by a decline in lower margin distribution sales.
Gross profit increased 9.1% to $1.11 billion, with gross margin improving to 36.9% from 36.5% in the prior year. This improvement resulted from favorable product mix as low margin distribution sales decreased, partially offset by increased plant and freight costs and $22.8 million in impairment charges related to non-promoted products. Operating income margin expanded significantly to 13.1%. SG&A expenses increased 10.6% to $526.8 million, primarily due to increases in employee compensation and launch costs for CREXONT and Brekiya. R&D expenses decreased 2.4% to $186.2 million, primarily due to a decrease in in-licensing and upfront milestone payments of $7.5 million.
The company generated strong operating cash flow of $340.0 million, an increase of $44.9 million from the prior year. Free cash flow (operating cash flow less capital expenditures) was $227.7 million. Investing activities used $112.3 million, primarily for purchases of property, plant and equipment ($70.1 million) and acquisition of intangible assets ($15.5 million). Financing activities used $31.5 million, primarily from net debt repayments. The balance sheet shows total assets of $3.68 billion, with current assets of $1.91 billion including $282.0 million in cash and cash equivalents. Total debt was $2.69 billion, consisting of $2.09 billion in term loans and $600.0 million in senior notes. The company had $595.2 million of available capacity under its revolving credit facility as of December 31, 2025.
The company estimates it will invest approximately $110.0 million during 2026 for capital expenditures to support and grow existing operations, primarily related to investments in manufacturing equipment, IT and facilities. Management believes current liquidity sources are sufficient to fund planned operations over the next 12 months. Key risks include potential impacts from tariff and trade developments, with ongoing Section 232 investigations into pharmaceutical imports that could result in tariffs, though finished dosage forms and API are currently exempt from recent global tariffs. The company is also subject to various legal proceedings and government investigations, including a nationwide opioids settlement agreement that became effective in January 2026 with initial payments made.